The main goal of our laboratory is the identification and characterization of signal transduction pathways that cause the dysregulation of growth and inhibition of apoptosis that characterize advanced human cancer. Our laboratory is dedicated to understanding the consequences of activation of these pathways and to using this information to develop mechanism-based therapeutic strategies.
Neal Rosen, MD, PhD
Research FocusPharmacologist Neal Rosen focuses on understanding biochemical mechanisms underlying phenotypes caused by tyrosine kinase activation in epithelial tumors and developing new therapeutic strategies.
EducationMD, PhD, Albert Einstein College of Medicine
- Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N. Cancer Discov. 2018 May;8(5):648-66 doi: 10.1158/2159-8290.CD-17-1452. Epub 2018 Feb 26.
- Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Yaeger R, Yao Z, Hyman DM, Hechtman JF, Vakiani E, Zhao H, Su W, Wang L, Joelson A, Cercek A, Baselga J, de Stanchina E, Saltz L, Berger MF, Solit DB, Rosen N. Cancer Res. 2017 Dec 1;77(23):6513-6523. doi: 10.1158/0008-547CAN-17-0768. Epub 2017 Sep 26.